Evidence map›Paper›PMID 42157237›Full record

ArticleRespiratory research2026

Butyrate attenuates house dust mite-induced activation of 16HBE bronchial epithelial cells in association with modulation of gene expression.

Roos E M Verstegen, Jennifer Hotie, Margarita Bikineeva, Suze van Brummelen, Johan Garssen, Gert Folkerts, Linette E M Willemsen

Abstract read
In one paragraph

Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Roos E M VerstegenDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands. r.e.m.verstegen@uu.nl.
Jennifer HotieDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands.
Margarita BikineevaDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands.
Suze van BrummelenDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands.
Johan GarssenDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands.
Gert FolkertsDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands.
Linette E M WillemsenDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, the Netherlands. l.e.m.willemsen@uu.nl.

Funding

Health~Holland 10.1.19.001 PPS
6 · The paper itself

Abstract

introductionThe airway epithelial barrier is the primary defense line of the lungs against allergens, such as house dust mite (HDM). A disrupted airway epithelial barrier plays a major role in asthma development. Short-chain fatty acids (SCFAs) are bacterial fermentation products that are associated with prevention against allergic inflammation. In this study, we aim to elucidate the direct preventative effects of SCFAs, particularly butyrate, on the HDM-induced bronchial epithelial cell (BEC) activation and barrier disruption in-vitro. MATERIALS AND

methodsImmortalized human 16HBE cells were exposed to HDM to simulate allergen-induced BEC inflammation. Pre-exposure of 1-1000 µM acetate, propionate or butyrate were studied for their ability to prevent epithelial activation. Histone deacetylase activity of cells was measured after pre-incubation with 100 or 200 µM butyrate and combined butyrate and HDM exposure. In a transwell, air-liquid interface (ALI)-culture, the effects of 100 µM butyrate on barrier integrity (transepithelial resistance (TEER) and 4 kDa FITC-dextran permeability) and inflammation were assessed in presence and absence of HDM. To gain broader insight in the effects of butyrate, RNA sequencing (RNAseq) was performed using 16HBE cells exposed to HDM, butyrate or both.

resultsPre-incubation with butyrate protected against the production of HDM-induced IL-8 (1-100 µM), CCL5 (1-100-1000 µM) and CCL20 (1-10-100 µM) by solid phase cultured 16HBE-cells, although 1000 µM butyrate increased IL-8 and CCL20 release. Pre-incubation with acetate and propionate showed similar effects. 100 µM butyrate did not suppress HDAC activity, while a dose of 200 µM butyrate did. In ALI-culture, HDM increased barrier permeability, and pre-incubation with 100 µM butyrate tended to prevent this. Additionally, HDM-induced CCL20 production was significantly decreased by butyrate. RNAseq revealed 100 µM butyrate to significantly affect biological processes of the cells linked to gene expression, mitochondrial function, cell division and cell signaling. These effects were observed both in absence and presence of HDM-exposure.

conclusionButyrate, at physiologically relevant doses, modulates gene expression of 16HBE cells, affecting amongst others post-transcriptional and mitochondrial pathways. In ALI-cultures, butyrate prevented epithelial activation (CCL20) and tended to prevent HDM-induced barrier defects. These findings highlight the relevance of SCFAs such as butyrate in maintaining bronchial epithelial cell homeostasis relevant for prevention and control of allergic airway disease.

Indexed as

BronchiButyratesEpithelial CellsPyroglyphidaeRespiratory MucosaAnimalsCell LineDose-Response Relationship, DrugGene Expression RegulationHumansButyratesAirway epithelial barrierAllergic asthmaButyrateHouse dust miteRNA sequencing

Identifiers

PMID42157237
PMCPMC13386805

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.